Member Info for BuenaVista

Seconded Thompi

Still time for that killer RNS this week HurstBot?

Trouble with your comfort blanket?

@russell, it takes a while to work out how this share moves ...but 4 years? This week's spike was a prime example. There was no news, just speculation. Best to buy when it's quiet and then sell into the spike.

Just another me-too herd mentality ADC. Which farmer will be the first to be brave enough to dive into the PDC pool?

I can't keep up with it and it's not even the end of the week yet.

Anyone presenting LSE's buy/sell data as a realistic measure of market activity is conning you.

Oh god, that Alan blurb is full of the usual forward-looking BS: opportunities for early commercialisation - potential to solve - with the potential for oral delivery - potential to make Nuvec® the delivery platform of choice - build a differentiated drug pipeline to drive long-term value - generate commercial progress through platform licensing deals and partnerships in the near term.

Just take whatever he spouts with a gritter lorry load of salt.

If there's one person to be distrusted more than AS, it's JBCo.

Probably going to partner with SPARTA Biodiscovery.

Oops! I need glasses!

@IFA90, hmm... I wonder why it wasn't declared in the RNS that he's Chair and CEO of SPARTA Biodiscovery, a company that characterises nanoparticles used to deliver medicines such as cancer drugs and therapeutic genetic information into the body: https://www.imperial.ac.uk/news/239811/new-startup-help-pharmaceutical-companies-develop/

We won't know who or when until HurstBot gives the nod. Latest guidance is 'later this week'. So shortly.

You've been reading watching's posts?!?!?!🤷🏻‍♂️

HurstBot's power of prediction is phuking phenomenal.

"Our US CEO is aware of this and to have long awaited news out later today"

HurstBot wrote "With the news flow accelerating, ..."

What news flow acclerating? There were 9 RNSes between 30 Sept and 30 Oct, one on 12 Dec, and nothing since. Yet 18 people rec'd this nonsense. Why?🤷🏻‍♂️

Nice try SW but the amount of revenue from the sale of Dx will affect whether the auditors will be able to sign Avacta off as a going concern this spring and not directly to the day-to-day MCap. You were right though in that the SP move is based purely on speculation.

And you're arrogant beonthelead, very, very, very arrogant and a smidgen ignorant, just enough so show what a supercilious puppy twat you are.

Yap! Yap! Yap!😂😂😂

LOL. Very brave Saint. Reminds me of my mother as she slipped into dementia and would come out with something like "They're leaving tomorrow" with absolutely no clue as to who 'they' were.

There are different uses for Affimer. Therapeutic use is a given and the IP for that will stay with Avacta. Diagnostic use is something else and can be licensed out or sold with Dx. Maybe Avacta want to retain complete control in some way over diagnostic use in oncology, maybe not, we'll know shortly.

@beinthelead, you seem to have zero faith in Avacta/Coris producing any LFT diagnostics using Affimers. How long do you think it should take Coris to announce the first Affimer LFT, or range of LFTs, considering their staffing resource and any development activities they may have been working on pre-acquisition?

Phew! We sold a dog there just in time.